Ad-hoc | 31 May 2002 07:31

aap Implantate AG english

aap boosts sales and earnings significantly Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– aap boosts sales and earnings significantly Profitable growth in Q1 / Triple-digit earnings growth / First quarter confirms success of restructuring program / New products with attractive growth potential aap Implantate AG testifies with its sales and earnings figures for the first quarter of 2002 to profitable growth that is well above the market level. First- quarter sales revenues increased by roughly 15% on the year to approx. EUR 3.42 million from EUR 2.98 million. EBITDA excluding stock options improved by 118% to EUR 1.2 million (previous year: EUR 540,000). Excluding acquisition-related write-downs totaling EUR 365,000 (previous year: EUR 403,000) and EUR 170,000 of stock options exercised and booked as expenses (previous year: EUR 208,000), EBIT amounts to EUR 895,000, up 286% on the previous year’s EUR 232,000. The consolidated DVFA/SG result adjusted to take these factors into account was EUR 380,000 in the review period (previous year: EUR 24,000) and DVFA/SG earnings per share were EUR 0.08 (previous year: EUR 0.01). Cash earnings adjusted in the same way totaled EUR 535,000 (previous year: EUR 372,000). Taking into account the above-mentioned special effects (stock options and acquisition-related write-downs), the figures are as follows. EBITDA increased to EUR 1.0 million (previous year: EUR 332,000). EBIT increased markedly by EUR 740,000 to EUR 361,000 (previous year: -EUR 379,000). The consolidated DVFA/SG result for the review period, EUR 34,000, was substantially higher than the previous year’s – EUR 355,000. DVFA/SG earnings per share were EUR 0.01 (previous year: -EUR 0.07). DVFA/SG cash earnings also improved in the review period to EUR 553,000 (previous year: EUR 395,000). end of ad-hoc-announcement (c)DGAP 31.05.2002 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: First-quarter progress reconfirms the successes of consistent enterprise-wide implementation of the restructuring program. The program is focused on cost optimization, sustained strengthening of the sales organization, integration of acquisitions, streamlining of the product portfolio and expansion in promising fields of competence. Strategic objectives for aap Implantate AG in the current financial year include intensifying sales activities in high-margin, high-growth foreign markets and extending product competencies into the orthobiological materials and bone cement/cementing technique segments. The bone replacement materials Cerabone, Cerabone granulate and Ostim that have already been granted approvals for the European market and are in the process of being launched constitute the starting-point for the extension of product competencies in this segment. On the basis of the positive trend that is already emerging after the first quarter and of successes so far achieved with the restructuring program, aap reconfirms its forecast of profitable double-digit sales growth excluding special effects (stock options and acquisition-related write-downs) for the full year 2002. ——————————————————————————– WKN: 506660; ISIN: DE0005066609; Index: Listed: Neuer Markt Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 310731 Mai 02